Study: Treatment of Male Pattern Baldness with Botulinum Toxin: A Pilot Study

Comment by Ethan:

This study is important because it reminds us that T conversion to DHT occurs in low oxygen environments, that the muscles (or anything) that constricts blood flow also reduces the availability of Oxygen in the scalp and dermal papilla.  Thus, relaxing these muscles, via botox (something I would not recommend since botox is a toxin), other approaches to relax the muscles and/or increase circulation and Oxygen levels include: various types of scalp massages, acupuncture, diet and nutrition, reducing inflammation, relaxation exercises etc is helpful to men with hair loss resulting from a genetic sensitivity to DHT.

 

 -:: This Abstract is posted here for posterity and archival purposes only ::-

Treatment of Male Pattern Baldness with Botulinum Toxin: A Pilot Study

Freund, Brian J. D.D.S., M.D.; Schwartz, Marvin D.D.S., M.Sc.

Plastic and Reconstructive Surgery . 126(5):246e-248e, November 2010.

doi: 10.1097/PRS.0b013e3181ef816d

Author Information

Crown Institute; Pickering, Ontario, Canada

Correspondence to Dr. Freund, 49 Main Street South, Uxbridge, Ontario L9P 1J4, Canada, freund@crowninstitute.com

This clinical trial has been registered as “Treatment of Male Pattern Baldness with Botulinum Toxin” at http://www.clinicaltrials.gov/ClinicalTrials.gov with identifier NCT00965640.

Sir:

We would like to present the results of an open-label pilot study using botulinum toxin type A (Botox; Allergan, Inc., Irvine, Calif.) for the treatment of androgenetic alopecia. This form of alopecia is believed to be caused by a genetically predisposed sensitivity of hair follicles to the toxic effects of dihydrotestosterone, a metabolite of testosterone. Medical treatment of androgenetic alopecia has previously only been moderately effective using systemic drugs such as finasteride, a 5α-reductase inhibitor.1

In this ethically approved study, 50 male subjects aged between 19 and 57 years with Norwood/Hamilton ratings of II to IV participated.2 The study was 60 weeks in duration, with 12 weeks of run-in followed by two treatment cycles of 24 weeks each. Subjects were injected with 150 units of Botox (5 units per 0.1 ml saline) into the muscles surrounding the scalp, including frontalis, temporalis, periauricular, and occipitalis muscles in equally divided doses over 30 injection sites.

The primary outcome measure was a change in hair count in a fixed 2-cm area using a method described by Canfield.3

Secondary outcome measures included hair loss, measured by having subjects collect loose hair from their pillow with a sticky lint roller, and subjective efficacy using a validated questionnaire. Statistical analysis entailed paired t tests of group means.

Forty subjects completed the study, and no adverse effects were reported. The treatment response rate was 75 percent.

Mean hair counts for the entire group showed a statistically significant (p < 0.0001) increase of 18 percent between baseline and week 48 (Table 1), similar to the results reported with Propecia (Merck, Whitehouse Station, N.J.).1 Hair regrowth was objectively visible in some subjects (Fig. 1). Secondary outcome measures were also significantly improved. The reduction in hair loss and increase in hair count did not show a statistically significant correlation. This suggested that longer retention of terminal hairs did not account for the increase in hair count.

Table 1
View Larger

Fig. 1
View Larger

Mechanistically, the scalp behaves like a drum skin with tensioning muscles around the periphery. These muscle groups—the frontalis, occipitalis, and periauricular muscles and to a minor degree the temporalis—can create a “tight” scalp when chronically active. Because the blood supply to the scalp enters through the periphery, a reduction in blood flow would be most apparent at the distal ends of the vessels, specifically, the vertex and frontal peaks. Areas of the scalp with sparse hair growth have been shown to be relatively hypoxic, have slow capillary refill, and to have high levels of dihydrotestosterone.4

Conceptually, Botox “loosens” the scalp, reducing pressure on the perforating vasculature, thereby increasing blood flow and oxygen concentration.

The enzymatic conversion of testosterone to dihydrotestosterone is oxygen dependent. In low-oxygen environments, the conversion of testosterone to dihydrotestosterone is favored; whereas in high-oxygen environments, more testosterone is converted to estradiol.4

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
An automatic insert of some related ads:

Thanks for your patronage. Article continues below:
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Blood flow may therefore be a primary determinant in follicular health. Strategically placed Botox injections appear able to indirectly modify this variable, resulting in reduced hair loss and new hair growth in some men with androgenetic alopecia.

DISCLOSURE

The investigators have received support in the form of unrestricted educational grants from Allergan Inc. (Irvine, Calif.) within the past 5 years. The authors hold intellectual property rights related to the process described in this study in both the United States and the European Union. This study was not supported by any commercial entity or government agency.

Brian J. Freund, D.D.S., M.D.

Marvin Schwartz, D.D.S., M.Sc.

Crown Institute

Pickering, Ontario, Canada

REFERENCES

1. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39:578–589.
Cited Here…

 

2. Norwood OT. Male pattern baldness: Classification and incidence. South Med J. 1975;68:1359–1365.
Cited Here…

 

3. Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin. 1996;14:713–721.
Cited Here…

 

4. Goldman BE. Transcutaneous PO2 of the scalp in male pattern baldness. Plast Reconstr Surg. 1996;97:1109–1116.
Cited Here…

 

Section Description

Viewpoints, pertaining to issues of general interest, are welcome, even if they are not related to items previously published. Viewpoints may present unique techniques, brief technology updates, technical notes, and so on. Viewpoints will be published on a space-available basis because they are typically less timesensitive than Letters and other types of articles. Please note the following criteria:

* Text—maximum of 500 words (not including references)

* References—maximum of five

* Authors—no more than five

* Figures/Tables—no more than two figures and/or one table

Authors will be listed in the order in which they appear in the submission. Viewpoints should be submitted electronically via PRS’ enkwell, at www.editorialmanager.com/prs/. We strongly encourage authors to submit figures in color.

We reserve the right to edit Viewpoints to meet requirements of space and format. Any financial interests relevant to the content must be disclosed. Submission of a Viewpoint constitutes permission for the American Society of Plastic Surgeons and its licensees and assignees to publish it in the Journal and in any other form or medium.

 

Source of text: http://stage-mobile.journals.lww.com/plasreconsurg/_layouts/oaks.journals.mobile/articleviewer.aspx?year=2010&issue=11000&article=00079&ContextualNavigationType=mostviewed

Abstract not available: http://www.ncbi.nlm.nih.gov/pubmed/21042071

Another full text available: http://journals.lww.com/plasreconsurg/Fulltext/2010/11000/Treatment_of_Male_Pattern_Baldness_with_Botulinum.79.aspx

 






--------------------------------------------
An automatic insert of a related ad:

Thanks for your patronage.
--------------------------------------------




If you enjoyed this article you may enjoy these as well

Tags: , , , , , , , , ,

Leave a Reply


four + = 5



Disclaimer: I must say this: The information presented herein is for informational purposes only. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements, making dietary changes, or before making any changes in prescribed medications.
All posts are strictly opinions meant to foster debate, education, comment, teaching, scholarship and research under the "fair use doctrine" in Section 107 of U.S. Code Title 17. No statement of fact is made and/or should be implied. Please verify all the articles on this site for yourself. The Information found here should in no way to be construed as medical advice. If You have a health issue please consult your professional medical provider. Everything here is the authors own personal opinion as reported by authors based on their personal perception and interpretation as a part of authors freedom of speech. Nothing reported here should be taken as medical advice, diagnosis or prescription; medical advice should only be taken from your health care provider. Consume the information found on this web site under your own responsibility. Please, do your own research; reach your own conclusions, and take personal responsibility and personal control of your health.